PF-Atlas › Clinical Trials › NCT06619561
A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease
Vimseltinib · Phase 2
Registry ID
NCT06619561
Phase
Phase 2
Status
Recruiting
Drug / intervention
Vimseltinib
Sponsor
Deciphera Pharmaceuticals, LLC
Start
2024-11-21
Enrollment
48
Locations
26
About this trial
The purpose of this study is to determine if vimseltinib is safe, tolerable and works effectively to treat adults with active moderate to severe cGVHD. Participants will be treated with vimseltinib in 28-day treatment cycles for approximately 2 years.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT06619561 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.